Abstract:BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has become an epidemic largely due to the worldwide increase in obesity. While lifestyle modifications and pharmacotherapies have been used to alleviate NAFLD, successful treatment options are limited. One of the main barriers to finding safe and effective drugs for long-term use in NAFLD is the fast initiation and progression of disease in the available preclinical models. Therefore, we are in need of preclinical models that (1) mimic the human manifestation of NAFLD and (2) have a longer progression time to allow for the design of superior treatments.AIM: To characterize a model of prolonged high-fat diet (HFD) feeding for investigation of the long-term progression of NAFLD.METHODS: In this study, we utilized prolonged HFD feeding to examine NAFLD features in C57BL/6 male mice. We fed mice with a HFD (60% fat, 20% protein, and 20% carbohydrate) for 80 wk to promote obesity (Old-HFD group, n = 18). A low-fat diet (LFD) (14% fat, 32% protein, and 54% carbohydrate) was administered for the same duration to age-matched mice (Old-LFD group, n = 15). An additional group of mice was maintained on the LFD (Young-LFD, n = 20) for a shorter duration (6 wk) to distinguish between age-dependent and age-independent effects. Liver, colon, adipose tissue, and feces were collected for histological and molecular assessments.RESULTS: Prolonged HFD feeding led to obesity and insulin resistance. Histological analysis in the liver of HFD mice demonstrated steatosis, cell injury, portal and lobular inflammation and fibrosis. In addition, molecular analysis for markers of endoplasmic reticulum stress established that the liver tissue of HFD mice have increased phosphorylated Jnk and CHOP. Lastly, we evaluated the gut microbial composition of Old-LFD and Old-HFD. We observed that prolonged HFD feeding in mice increased the relative abundance of the Firmicutes phylum. At the genus level, we observed a significant increase in the abundance of Adercreutzia, Coprococcus, Dorea, and Ruminococcus and decreased relative abundance of Turicibacter and Anaeroplasma in HFD mice.CONCLUSION: Overall, these data suggest that chronic HFD consumption in mice can mimic pathophysiological and some microbial events observed in NAFLD patients.

Co-Treatment with Cefotaxime and High-Fructose Diet Inducing Nonalcoholic Fatty Liver Disease and Gut Microbial Dysbiosis in Mice

Mechanisms of Nonalcoholic Fatty Liver Disease Induced by Antibiotic Resistance and Evaluation of Bacteriophag-Efficacy

Antibiotics attenuate diet-induced nonalcoholic fatty liver disease without altering intestinal barrier dysfunction

Dietary capsaicin and antibiotics act synergistically to reduce non-alcoholic fatty liver disease induced by high fat diet in mice

The Protective Effect and Mechanism of the FXR Agonist Obeticholic Acid Via Targeting Gut Microbiota in Non-Alcoholic Fatty Liver Disease.

Gut microbiota induces hepatic steatosis by modulating the T cells balance in high fructose diet mice

Impact of Vancomycin Treatment and Gut Microbiota on Bile Acid Metabolism and the Development of Non-Alcoholic Steatohepatitis in Mice

A High-Fat Diet Increases the Characteristics of Gut Microbial Composition and the Intestinal Damage Associated with Non-Alcoholic Fatty Liver Disease

The chronic consumption of dietary fructose promotes the gut Clostridium species imbalance and bile acid alterations in developing nonalcoholic fatty liver disease

Co-interventions with Clostridium Butyricum and Soluble Dietary Fiber Targeting the Gut Microbiota Improve MAFLD Via the Acly/Nrf2/NF-κB Signaling Pathway.

Antibiotic altered liver damage induced by aflatoxin B1 exposure in mice by modulating the gut microbiota

Prolonged high-fat-diet feeding promotes non-alcoholic fatty liver disease and alters gut microbiota in mice

Antibiotic effects on gut microbiota modulate diet‐induced metabolic dysfunction‐associated steatohepatitis development in C57BL/6 mice

Gut-liver axis modulation in fructose-fed mice: a role for PPAR-alpha and linagliptin

Caffeic Acid Prevents Non-Alcoholic Fatty Liver Disease Induced by a High-Fat Diet Through Gut Microbiota Modulation in Mice.

Tangshen formula targets the gut microbiota to treat non-alcoholic fatty liver disease in HFD mice: A 16S rRNA and non-targeted metabolomics analyses

Intestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis

Long-term Effects on Liver Metabolism Induced by Ceftriaxone Sodium Pretreatment.

Microbiota Dysbiosis and Gut Barrier Dysfunction Associated with Non-Alcoholic Fatty Liver Disease Are Modulated by a Specific Metabolic Cofactors' Combination

Role of Probiotics in Gut Microbiome and Metabolome in Non-Alcoholic Fatty Liver Disease Mouse Model: A Comparative Study

Intestinal Farnesoid X Receptor Signaling Promotes Nonalcoholic Fatty Liver Disease